CROI 2017 Program and Information

Program and Agenda

445 CELLULAR HIV-1 DNA LEVELS AFTER 96WEEKS OF SWITCH TO ATV/R+3TC IN THE ATLAS-MTRIAL Francesca Lombardi 1 , Simone Belmonti 1 , Eugenia Quiros-Roldan 2 , Alessandra Latini 3 , Chiara Picarelli 1 , Arianna Emiliozzi 1 , Massimiliano Fabbiani 4 , Roberto Cauda 1 , Andrea De Luca 5 , for the AtLaS-M study group 1 Catholic Univ of Sacred Heart, Rome, Italy, 2 Spedali Civili di Brescia, Brescia, Italy, 3 IFO S. Gallicano Inst (IRCCS), Rome, Italy, 4 Univ of Milan, Milan, Italy, 5 Siena Univ Hosp, Siena, Italy 446 DYNAMICS OF VIRAL LOAD AND CYTOKINESWHEN ART IS INITIATED SOON AFTER HIV ACQUISITION Trupti I. Gilada 1 , Javier R. Lama 2 , Rachel A. Bender Ignacio 3 , Ricardo Alfaro 2 , Carmela Ganoza 2 , Angela K. Ulrich 4 , Socorro M. Harb 3 , Rogelio M. Valdez 4 , Robert Coombs 3 , Ann Duerr 4 1 Unison Medicare and Rsr Cntr, Mumbai, India, 2 Asociacion Civil Impacta Salud y Educacion, Lima, Peru, 3 Univ of Washington, Seattle, WA, USA, 4 Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA 447 VALACYCLOVIR DOES NOT ATTENUATE CD4 COUNT DECLINE IN CART-UNTREATED HIV INFECTION 1 St. Michael’s Hosp, Toronto, Ontario, Canada, 2 Univ of Toronto, Toronto, Ontario, Canada, 3 Toronto General Rsr Inst, Toronto, Ontario, Canada, 4 Inst Nacional de Infectologia (INI-Fiocruz), Rio de Janeiro, Brazil, 5 Centro de Referência e Treinamento em DST/AIDS-SP, Sao Paulo, Brazil, 6 Fundación Huesped, Buenos Aires, Argentina, 7 St. Stephen’s AIDS Trust, London, UK, 8 Brighton & Sussex Univ Hosps NHS Trust, Brighton, UK, 9 Canadian HIV Trials Network, Vancouver, British Columbia, Canada, 10 Univ of Toronto, Toronto, Ontario, Canada 448 RALTEGRAVIR/EMTRICITABINE/TENOFOVIR INHIV-2 INFECTION (ANRS 159VIH-2 PILOT TRIAL) Sophie Matheron 1 , Diane Descamps 1 , Sébastien Gallien 2 , Amel Besseghir 3 , Roland Tubiana 4 , Florence Damond 1 , Fideline Collin 3 , Francoise Brun-Vezinet 1 , Genevieve Chene 3 , for the ANRS 159 VIH2 trial Study Group 1 Hopital Bichat-Claude Bernard, AP-HP, Paris, France, 2 Hopital Saint Louis, AP-HP, Paris, France, 3 INSERM, Bordeaux, France, 4 Hopital Pitié-Salpétrière, AP-HP, Paris, France 449LB LONG-ACTING IBALIZUMAB IN PATIENTSWITHMULTI-DRUG RESISTANT HIV-1: A 24-WEEK STUDY Stanley Lewis 1 , Jeffry Fessel 2 , Brinda Emu 3 , Shannon Schrader 4 , Princy Kumar 5 , Gary J. Richmond 6 , Steven Weinheimer 1 , Christian Marsolais 7 1 TaiMed Biologics USA, Irvine, CA, USA, 2 Kaiser Permanent Med Cntr, San Fransisco, CA, USA, 3 Yale Univ, New Haven, CT, USA, 4 Schrader Clinic, Houston, TX, USA, 5 Georgetown Univ, Washington, DC, 6 Gary J Richmond MD PA, Ft Lauderdale, FL, USA, 7 Theratechnologies, Inc, Montreal, Canada 450LB A PHASE 2 OPEN-LABEL TRIAL OF ANTIBODY UB-421 MONOTHERAPY AS A SUBSTITUTE FOR HAART Chang-Yi Wang 1 , Wingwai Wong 2 , Hung-Chin Tsai 3 , Yen-Hsu Chen 4 , Mei-June Liao 5 , Shugene Lynn 6 , for the United BioPharma UB-421 Clinical and Research Team 1 United Biomed, Inc, Hauppauge, NY, USA, 2 Taipei Veterans General Hosp, Taipei, Taiwan, 3 Kaohsiung Veterans General Hosp, Kaohsiung, Taiwan, 4 Kaohsiung Med Univ and Hosp, Kaohsiung, Taiwan, 5 United Biopharma, Inc, Hsinchu, Taiwan, 6 UBI Asia, Hsinchu, Taiwan Darrell H. Tan 1 , Janet M. Raboud 2 , Leah Szadkowski 3 , Beatriz Grinsztejn 4 , Jose Valdez Madruga 5 , Pedro Cahn 6 , Simon Barton 7 , Amanda Clarke 8 , Wendy Zubyk 9 , Sharon Walmsley 10

Poster Sessions • Tuesday

CROI 2017 87